Cyclacel Pharmaceuticals entered into a Securities Purchase Agreement with David E. Lazar to sell 1,000,000 shares of Series C and 2,100,000 shares of Series D Convertible Preferred Stock for $3.1 million, which will be used to settle liabilities and for corporate purposes; David Lazar also becomes the interim CEO following the resignation of Spiro Rombotis.